Three Essays In Search of a Point

I just received a job market packet from a large university, which I will not name. The dissertations include "Three Essays in Applied Economics," "Three Essays in Econometrics, and "Essays in Econometrics." Don't worry. There were three essays in "Essays in Econometrics."  

Dealing with the Situation

Here is an example of an attempt at a private solution to a negative externality.

Why Economics Needs History

Barry Eichengreen's INET talk

NEP-HIS

Bernardo Batiz-Lazo's blog on new papers in economic history.

Trust Companies in the Panic of 1907

I recently posted "Sometimes Bad Things Happen to Good Trust Companies: A Reexamination of the Trust Company Panic of 1907" on SSRN

Abstract

The runs on trust companies during the Panic of 1907 have been blamed on unregulated financial innovation. New York trust companies are said to have taken advantage of gaps in regulation to engage in risky behavior, ultimately causing depositors to lose confidence in trust companies. This paper shows that there was not a general loss of confidence in trust companies. Runs were concentrated on a specific group of trust companies: the uptown trust companies. But there is no evidence of mismanagement or unusually risky asset allocation among these companies. Instead, it was the nature of their deposits that made them more susceptible to runs. While traditional trust companies focused on small numbers of large deposits from businesses, the uptown trust companies had large numbers of household deposits.

His Dark Materials and Economic History

According to the documents at the end of Philip Pullman's Once Upon a Time in the North Lyra went on to study economic history. Her dissertation for an M.Phil in Economic History was titled "Developments in patterns of trade in the European Arctic region with particular reference to independent cargo balloon carriage (1950-1970)."

Today in American Economic History

1794 Eli Whitney received a patent for the cotton gin.

1900 Congress passed The Gold Standard Act

government granted monoply

The FDA just granted KV Pharmaceutical a monopoly on the sale of a drug to prevent premature births. For years it had been produced by pharmacies that sold it for $10 to $20. Doctors can no longer use those versions of the drug. KV is increasing the price of a shot from $10 to $1,500. Read the story here.